Tizanidine
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
mecamylamine
Ganglionic blocking agent (secondary amine, Nn receptor antagonist) · Antihypertensive
Ganglionic blocking agent (secondary amine, Nn receptor antagonist)Antihypertensive
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- TizanidineSevereDatabaseDDInter
Mechanism
A secondary amine with a channel block mechanism similar to hexamethonium, impairing ganglionic transmission.
Indications
Moderate to severe hypertensionSmoking cessation (tried, not approved)
Dosing
- Adult
- Initial 2.5 mg twice daily, increased in increments of 2.5 mg/day at intervals of 2 or more days until desired blood pressure response is achieved.
Pharmacokinetics
Bioavailability
Good oral bioavailability
Excretion
Concentrates in the liver and kidney and is excreted slowly in an unchanged form
Side effects
Common
Constipation
Serious
- Numerous undesirable side effects due to generalized ganglionic blockade
- Paralytic ileus
- Reduced bowel activity
- Postural hypotension
Drug interactions
11 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Ask House about mecamylamine
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team